sheet with the US firm EQGen Biomedical regarding EQSTEM, Xintela’s
veterinarian joint disease treatment. We expect details to be disclosed once
EQGen Biomedical secures funding and the parties announce a license agreement.
We therefore maintain our risk-adjusted motivated value of SEK 1.30 per share.
Aktuellt
SENASTE
